Search Results
Aug 18, 2026, 09:56 ET Parkinson's Foundation Invests More Than $7.5 Million in Research Grants
than $7.5 million across 55 grants to accelerate cutting-edge Parkinson's disease (PD) research. Through these research grants, the Foundation funds scientists conducting innovative studies across various aspects of PD to bring forward new therapies, treatments and ultimately a cure for the 10 million
More news about: Parkinson's Foundation
Aug 17, 2026, 09:56 ET 科倫博泰宣佈2026年中期業績
佳泰莱®)目前已獲批上市4項適應症，分別用於治療2L+ TNBC、2L/3L EGFR突變型NSCLC、2L+ HR+/HER2- BC；2項新增適應症申請獲受理，分別用於聯合帕博利珠單抗治療1L PD-L1陽性NSCLC，以及治療1L TNBC。期內取得的臨床進展如下：治療2L+ HR+/HER2- BC已獲批上市治療1L TNBC及1L PD-L1陽性NSCLC的新增適應症申請已獲受理治療1L PD-L1陰性非鱗狀NSCLC的OptiTROP-Lung06中國註冊性試驗達到主要終點治療2L+ EC的TroFuse-005全球性
More news about: 科倫博泰
Aug 17, 2026, 08:00 ET OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
novel and well-validated targets across oncology and immunological diseases. Among them, AI-081 is a fully owned bispecific antibody candidate targeting PD-1 and VEGF. ONC-841 is a first-in-class anti-SIGLEC-10 antibody currently in a Phase 2 trial for oncology indications and a Phase 1 trial for neurodegenerative
More news about: OncoC4
Aug 17, 2026, 07:18 ET Kelun-Biotech Announces 2026 Interim Results
cytotoxin or immuno-agonist or degrader combinations, among others.Doubling down on ADC + IO therapies, including the combination of ADCs with PD-(L)1 or PD-1/VEGF agents, as well as the development of drug candidates with synergetic MoAs within one ADC compound.Beyond oncology, the Company
More news about: Kelun-biotech
Aug 17, 2026, 06:44 ET HenliusとSandoz、バイオシミラー・プラットフォームのグローバルな価値を最大限に引き出すための戦略的提携を締結
す。Henliusの主力製品であるセルプルリマブ（商品名：ヘトロニフライ®、 ：欧州）は、小細胞肺がんの一次治療および胃がんの周術期治療において承認された、世界初の抗PD-1モノクローナル抗体です。現在までに、世界50の市場で承認されており、 グローバル展開プロセスは加速しています。これと並行して、PD-L1 ADC「HLX43」や新規エピトープを標的とする抗HER2モノクローナル抗体「dulpatatug（HLX22）」など、将来性が期待される複数の革新的な候補薬が、世界規模での主要臨床開発を進めています。総生産能力84,000Lのバイオ医薬品製造ネットワークと、中国、
More news about: Henlius
Aug 17, 2026, 05:27 ET AMERICAN PARKINSON DISEASE ASSOCIATION TO HOST FOURTH ANNUAL VIRTUAL PARKINSON'S CONFERENCE
empower, and engage people with Parkinson's disease (PD), care partners, family members, and friends. The conference will offer attendees the opportunity to hear directly from leaders in PD treatment and research while connecting with others in the PD community for support, inspiration, and guidance.
More news about: American Parkinson Disease Association, Inc.
Aug 17, 2026, 00:08 ET Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
over 30 clinical trials ongoing globally. Henlius' core product, serplulimab (trade name: Hetronifly® in Europe), is the world's first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and for perioperative gastric cancer. Up to date, it has
More news about: Henlius
Aug 13, 2026, 07:00 ET Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating a favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The Company has received the IND clearance
More news about: Accro Bioscience Inc.
Aug 12, 2026, 09:00 ET Cellular Intelligence Names Single-Cell Biology Pioneer Arjun Raj, Ph.D., Chief Scientific Officer and Scientific Co-Founder
connects its foundation-model platform to a direct path to patients. In May, the company acquired STEM-PD, an investigational Phase 2-ready Parkinson's disease cell therapy program, from Novo Nordisk. STEM-PD is both a therapy the company is working to advance for patients and a proving ground for the company's
More news about: Cellular Intelligence
Aug 12, 2026, 08:17 ET Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment
months in PD-L1-positive NSCLC, compared with 5.8 months for pembrolizumab, making it the first drug to demonstrate a positive Phase III result against the leading PD-1 therapy.These results position ivonescimab as a cornerstone of the immuno-oncology 2.0 era. Across comparisons with PD-1 monotherapy,
More news about: Akeso, Inc.
Aug 12, 2026, 06:05 ET RyboDyn Unveils a Hidden Human Proteome and a New Universe of Actionable Cancer Targets
the supply of new therapeutic axes worth targeting. When new cancer biology is discovered, it leads to a new wave of blockbuster drugs (e.g. HER2, PD-1/PD-L1). Of the roughly 13,600 drug-target pairs in the global preclinical and clinical pipeline, a quarter of these converge on just 38 biological targets
More news about: RyboDyn
Aug 12, 2026, 03:01 ET Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research
advance.If validated through additional studies, this mechanism could also be explored in combination with immune checkpoint inhibitors targeting PD-1 or PD-L1, with the goal of broadening or prolonging antitumor immune activity. These findings are preclinical and require confirmation in additional animal
More news about: SENHWA BIOSCIENCES, INC.
Aug 11, 2026, 17:30 ET Franco-Nevada Reports Q2 2026 Results
Our 2026 guidance assumes the following commodity prices: $4,500/oz Au, $75.00/oz Ag, $2,000/oz Pt, $1,650/oz Pd, $100/tonne Fe 62% CFR China, $70/bbl WTI oil and $3.00/mcf Henry Hub natural gas. GEOs for the 2026 period are calculated based on fixed conversion ratios
More news about: Franco-Nevada Corporation
Aug 11, 2026, 11:06 ET "Crossing the 49th Parallel" -- the Cross-Border Retirement Guide -- Arrives on Audible
https://www.audible.com/pd/Crossing-the-49th-Parallel-Audiobook/B0HC4LD3BV ($15.34, or free with a 30-day Audible trial). Print and Kindle editions remain available on Amazon. Learn more
More news about: Lucas Wennersten
Aug 11, 2026, 08:57 ET Parkinson's Foundation Announces Second Cohort of Nurse Practitioner Fellowship in Movement Disorders
Emory University. Applications are now open for nurse practitioners (NP) who are interested in pursuing a career in Parkinson's disease (PD) care and research. Three NPs will be selected for the 2027 fellowship cohort and will complete a year-long program at Emory Healthcare's Movement Disorders
More news about: Parkinson's Foundation
Aug 11, 2026, 07:30 ET Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Keynote-522, the standard neoadjuvant treatment for TNBC includes systemic chemotherapy (anthracyclines, cyclophosphamide, paclitaxel, carboplatin) and the anti-PD-1 monoclonal antibody pembrolizumab. pCR rates range from 50% to 65%, depending on tumor size. Rates are generally lower in the larger-sized tumors or
More news about: Intensity Therapeutics Inc.
Aug 11, 2026, 06:00 ET Cambrex Milan comemora seu 80º aniversário com a construção de novas instalações de P&D de US$ 30 milhões
multimedia:https://www.prnewswire.com/br/comunicados-para-a-imprensa/cambrex-milan-comemora-seu-80-aniversario-com-a-construcao-de-novas-instalacoes-de-pd-de-us-30-milhoes-302847241.htmlFONTE
More news about: Cambrex
Aug 10, 2026, 18:01 ET REPL INVESTOR ALERT: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Replimune Class Action Lawsuit
Biologics License Application ("BLA") for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen. The complaint alleges that Replimune also claimed that "[d]uring
More news about: Robbins Geller Rudman & Dowd LLP
Aug 10, 2026, 10:00 ET REPL Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Replimune Group, Inc.
Biologics License Application ("BLA") for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen. The Company claimed that "[a]dditional information, data and analyses were included in the resubmission which will be part of the
More news about: Robbins LLP
Aug 10, 2026, 09:50 ET THE LUSTGARTEN FOUNDATION AND BREAK THROUGH CANCER ANNOUNCE NEW CLINICAL TRIAL EVALUATING KRAS-TARGETED IMMUNOTHERAPY STRATEGY FOR PANCREATIC CANCER
investigational therapy ELI-002 7P, from Elicio Therapeutics, Inc., in combination with standard neoadjuvant mFOLFIRINOX chemotherapy, with or without the PD-1 inhibitor tislelizumab. Researchers will examine not only the safety and feasibility of the approach but also generate detailed molecular and immune
More news about: Lustgarten Foundation
Aug 10, 2026, 06:45 ET Blue Moon Announces Initial Results from Ongoing Infill Drilling Campaign at its Nussir Project and Further Deep Drilling Exploration Results
true thickness estimates, are presented in Table 1. In addition to the grades listed below, NUS-DD-26-08 intersected 0.6 m at 0.69 g/t Pt and 0.42 g/t Pd. This provides additional insight to previous showings of palladium and platinum previously encountered in hole NUS-DD-14-001.Table
More news about: Blue Moon Metals
Aug 10, 2026, 00:05 ET Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
create significant and urgent unmet clinical needs. These include the limited efficacy of immuno-oncology approaches in PD-L1-negative patients and in those who develop resistance to anti-PD-1 therapy, as well as the safety constraints of ADCs that restrict both therapeutic benefit and the number of treatment
More news about: Akeso, Inc.
Aug 07, 2026, 10:57 ET Renew Biotechnologies Publishes Peer-Reviewed Research Advancing Cell-Type-Associated Biomarkers of Neurodegeneration
cognitive impairment (MCI), PD, ALS, and healthy controls. Across 137 blood samples, the proof-of-concept study identified disease-associated cfDNA signatures corresponding to selectively vulnerable neuronal populations, including cortical neurons in AD, dopaminergic neurons in PD, and spinal motor neurons
More news about: Renew Biotechnologies
Aug 06, 2026, 21:58 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
for its drug RP1 (vusolimogene oderparepvec) in combination with Bristol Myers Squibb's PD-1 inhibitor Opdivo for adults with unresectable advanced cutaneous melanoma who experience disease progression after a PD-1-blocking antibody-based therapy. Specifically, the FDA's briefing documents said that
More news about: Pomerantz LLP
Aug 06, 2026, 19:00 ET Energenesis Biomedical and Taiwan Tanabe Seiyaku Enter Joint Development Agreement for ENERGI-F703DFU
cream for Epidermolysis bullosa (Phase II); granted FDA Orphan Drug and Rare Pediatric Disease designations and EMA orphan designationENERGI-F705PD – Oral sustained-release tablet for Parkinson's disease (Phase II IND)ENERGI-F701 – Topical tonic for alopecia (Phase II completed)About
More news about: Energenesis Biomedical Co., Ltd.